Abstract
Background: Neuroendocrine carcinoma is an uncommon histology for breast cancer. Case Report: Our patient underwent right quadrantectomy for a neuroendocrine carcinoma in 1984 and had a bone relapse 30 years later. After thorough pathological and immunohistochemical analysis the diagnosis was confirmed and HER2 amplification was observed. Here we discuss the management, rationale and results of HER2-targeted therapy in advanced neuroendocrine breast carcinoma.
Original language | English |
---|---|
Pages (from-to) | 424-426 |
Number of pages | 3 |
Journal | Breast Care |
Volume | 11 |
Issue number | 6 |
DOIs | |
Publication status | Published - Dec 1 2016 |
Keywords
- Breast carcinoma
- Neuroendocrine carcinoma
- Trastuzumab
ASJC Scopus subject areas
- Surgery
- Oncology